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Dubček University of Trenčín, Trenčín, SlovakiaA B S T R A C TObjectives: To provide valuable local data on the economic burden of
rotavirus gastroenteritis (RVGE) for decision making on introduction
of rotavirus vaccination in Central European countries. Methods: We
conducted a retrospective patient hospital chart review during the
winter RVGE peak in the Czech Republic (n ¼ 109), Hungary (n ¼ 109),
Poland, (n ¼ 112), and Slovakia (n ¼ 115) to estimate resource use and
associated costs from the payer’s perspective in children younger
than 5 years with severe RVGE requiring hospitalization. Microcosting
analysis was used to estimate the average costs of treating RVGE
inpatients including pre- and posthospitalization costs. Results: The
average cost of treatment was €476, €316, €741, and €594 in the Czech
Republic, Hungary, Poland, and Slovakia, respectively. Extrapolating
these costs to the total number of RVGE hospitalizations gives annual
cost estimates of €2.1 million, €1.5 million, €13.2 million, and €1.5
million, respectively. The main component of expenditure in all the
four countries is the hospital stay, but wide variation among countriesee front matter Copyright & 2016, International S
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ons.org/licenses/by-nc-nd/4.0/).
1016/j.vhri.2016.07.005
est: A. Tichopad and J. Müllerová are employees of
nies to complete the work presented in this article
ntract, for providing her support, advice, professio
e partaking research sites. She also received hono
er projects and was the investigator in clinical s
GSK group of companies and holds stock optio
lare no conﬂicts of interest.
opad@kantarhealth.com.
ndence to: Ales Tichopad, Kantar Health s.r.o., Krewas observed (total cost of treating RVGE in hospital was almost 2.5-
fold higher in Poland than in Hungary). In countries with diagnosis
related group (DRG) costs available, the best agreement between real
resource-use–driven costs and the DRG cost was found in the Czech
Republic and Hungary, with differences of only €22 and €33, respec-
tively. In Poland, the microcosting indicated higher overall costs
incurred in hospital than the DRG cost, with a difference exceed-
ing €190. Conclusions: Hospitalization of children with RVGE repre-
sents a substantial economic burden for the national health systems
in these countries.
Keywords: chart review, cost burden, incidence, rotavirus
gastroenteritis, vaccination, Visegrad region.
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Rotavirus (RV) is one of the leading causes of gastroenteritis,
often associated with severe diarrhea and dehydration, in infants
and young children throughout the world [1]. RV infection among
children younger than 5 years is associated with signiﬁcant
mortality, predominantly in countries with insufﬁcient health
care infrastructure and access [2]. It causes an estimated 6,550deaths (range 5,671–8,989) and 146,287 hospital admissions (range
38,374–1,039,843) each year in children younger than 5 years in
the World Health Organization (WHO) European region [3]. The
average annual mortality rate for children younger than 5 years
in this region is 2 per 100,000, calculated from the United Nations
Children’s Fund data [4].
RV caused 25.3% to 63.5% of acute gastroenteritis cases in
children younger than 5 years in Western Europe, with a peakociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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countries [5]. The ﬁrst infection is usually the most severe [6], and
most symptomatic episodes occur in young children between the
ages of 3 months and 2 years. It was estimated that 3.6 million
episodes of RV disease occur annually among the 23.6 million
children younger than 5 years in the European Union (EU),
accounting for more than 87,000 hospitalizations and almost
700,000 outpatient visits per year [7].
Many countries in Europe have implemented the vaccination
of healthy infants against RV as recommended by the WHO in
2009 [8,9], including Austria, Belgium, Estonia, Finland, Germany,
Greece, Latvia, Luxembourg, Norway, and the United Kingdom, as
well as some regions in Italy and Sweden.
The Visegrad Group (V4) is a group of four former socialist
countries in the central part of Europe: the Czech Republic, Hungary,
Poland, and Slovakia. It represents an integrated sociopolitical region
with similar history, economy, and health care systems. All four
have been members of the EU since 2004. The underlying epidemi-
ology and health care may have been substantially shaped by the
residual cultural and economic inﬂuences of the past, yet both have
rapidly improved during the past two decades, largely as a result of
decentralizing the health care sector in varying degrees [10]. With the
increasing signiﬁcance of health technology assessment procedures
in all EU countries, there is a fundamental need for solid underlying
evidence in any further consideration of reimbursement of innova-
tive medicinal products [11].
In the most recent article from the region, the incidence of
rotavirus gastroenteritis (RVGE) per 100,000 in children younger
than 5 years was reported as 649.1 in the Czech Republic, 168.55 in
Hungary, and 1125.64 in Slovakia. The underlying data, however,
are most likely underreported [12,13]. Moreover, testing the dis-
ease etiology of gastroenteritis is not mandatory and not system-
atically performed, especially for patients treated in an outpatient
setting without referral to a hospital. Moderate RVGE cases treated
as outpatients or mild cases treated at home are therefore largely
unknown. Severe RVGE cases requiring hospitalization may be
better captured within the national databases hosted by epidemi-
ology surveillance programs or national health care fund records,
but these may not fully reﬂect the real burden [7].
In this article, we report results from a burden-of-disease
study based on a retrospective patient chart review conducted in
patients admitted to hospitals in the V4 during 2013. Health
resource use in prehospitalization and posthospitalization care
was also captured. In addition, we attempted to establish, by
means of extrapolation, the overall burden of disease for all cases
of RVGE, regardless of the point of care, using empirical ratios
between the three RVGE severity classes.Methods
Retrospective Patient Chart Review
The study was based on a multicenter, international, retrospec-
tive patient chart review involving 14 hospital centers in the
Czech Republic, 10 in Hungary, 9 in Poland, and 14 in Slovakia. In
total, 445 patient charts from the Czech Republic (n ¼ 109),
Hungary (n ¼ 109), Poland (n ¼ 112), and Slovakia (n ¼ 115) were
randomly selected and studied. The selection of centers involved
in the study aimed to achieve a good representation of all
national regions and a good distribution between city and rural
centers in the sample. Inclusion criteria for the selection of
patient charts restricted the reported cases to all hospitalized
children younger than 60 months (at diagnosis of RVGE) with
RVGE as deﬁned by either the Ninth or Tenth revision code of the
International Classiﬁcation of Diseases (ICD-9 or ICD-10), conﬁrmed
by an etiology test. The complete patient charts were requiredto be available to provide information on previous medical care
and/or subsequent referral, if any. Nosocomial infections were
not considered in this study. Because of the local regulations on
noninterventional retrospective chart reviews, no informed con-
sent was required. The project approval was issued within a
centralized course of proceedings by an ad hoc body competent
to examine the dossier under the local regulations relevant in
this matter. No approval was required in Poland.
Because of the seasonal character of RVGE, the preferred
method was to select 10 cases randomly from the list of patients
hospitalized for RVGE in the winter RVGE peak between January 1
and May 31, 2013. The physician provided an anonymized list of
identiﬁers of all patients to the research organization and
received back a list of randomly selected patients to include in
the study. The sample size was selected on a pragmatic basis,
and the study planned to capture data from a minimum of 100
patients hospitalized with RVGE in each of the countries. Data
were entered by doctors in an electronic case report form and
immediately transferred and stored within a secured database.
The method used in RV testing was selected from a list contain-
ing the following options: enzyme-linked immunosorbent assay,
electron microscopy, latex agglutination, polymerase chain reac-
tion, immunochromatography, or any other (which needed to be
speciﬁed). There was no need of any further speciﬁcation of the
manufacturer, speciﬁcity, and sensitivity.
The database was locked as soon as all the centers conﬁrmed
that they had provided data on all available patients, when the
total number of patients within each national database reached
at least 100.
Resource Use Analysis
From each individual patient chart, physicians transferred informa-
tion into the electronic case report form relating to the age of the
patient, length of hospital stay, type of ward, medication used, route
of admission and previous treatment, examinations and diagnostic
tests performed, and subsequent referral or follow-up. To ensure
sensitivity to various cost sources, speciﬁc types of hospital wards
were selected in each country. In the Czech Republic and Slovakia,
data were obtained for patients hospitalized in pediatric wards or in
infectious disease wards. In Hungary, data were obtained for patients
hospitalized in pediatric gastroenterology or in infectious disease
wards. In Poland, children are hospitalized only in pediatric wards.
Therefore, to be sensitive to cost variations, hospitals in Poland were
selected according to their regional importance, that is, county
hospital, regional hospital, or university hospital.
Costs
Costs were considered solely from the perspective of the payer.
The costs were categorized by phase of treatment: 1) before
hospitalization, associated with the initial physician contact
followed by referral to hospital; 2) during hospitalization; and 3)
posthospitalization but still associated with the cause of hospital-
ization. The total cost per RVGE case treatment encompassed the
following items: prehospitalization cost (cost of a single consult-
ing), admission cost, etiology test cost, medication cost, exami-
nations cost, interventions cost, posthospitalization cost, and the
cost of hospital stay. The overall cost burden of severe RVGE in
the four countries was estimated on the basis of the national
epidemiological data provided on our formal demand by the
relevant data holders managing local health insurance funds and
incidence registers. Indirect costs were not considered. In three
countries, national diagnosis related group (DRG) codes were
available and were used to estimate the reimbursement level
for each treated case. In the Czech Republic and Poland, more
than one DRG code was recorded and a weighted mean was used
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average DRG cost for ICD-10 code A08.0 (rotavirus enteritis) was
obtained from the National Health Fund. In Slovakia, where no
DRG system is in place, the arithmetic mean of reimbursement
ﬁgures received during an investigation in ﬁve hospitals was
calculated and used for all patients in the study regardless of
hospitalization facility (referred to in this article as “contractual
reimbursement”) [14]. Nevertheless, the contractual reimburse-
ment is speciﬁc to each hospital, often based on conﬁdential
agreements between the respective hospital and a health fund.
Microcosting analysis was used to estimate total costs includ-
ing prehospitalization and posthospitalization costs. In the Czech
Republic [15], Slovakia [16], and Hungary [17], resource use data on
examinations, test procedures, and medication [18–23] were asso-
ciated with reimbursement levels retrieved from national reim-
bursement lists governed by national law acts and implementing
decrees. The costs of hospital stay in the Czech Republic were
obtained on the basis of a length-of-stay principle as described in
the Collection of Laws of the Czech Republic [24,25]. In Poland, the
cost of all microcosting items was calculated on the basis of the
hospitals’ price lists published on the Internet [26–31]. These price
lists are usually used in cases in which medical care is provided to
uninsured beneﬁciaries. For this reason, expenses determined by
this method may diverge slightly from the “real prices” of medical
care as considered from the payer’s perspective. These, however,
were the only reliable sources providing detailed accounts suitable
for use in microcosting.
Burden of Disease
Reporting of infectious diseases is mandatory in the Czech
Republic. The obligation to report is based on Act No. 258/2000
on the protection of public health. In 2011, 4494 RVGE cases in
children younger than 5 years were captured within the EPIDAT
surveillance system under the ICD-10 code A08.0. RV testing is
mostly conducted in inpatient cases and therefore the cases
reported to EPIDAT are almost exclusively severe.
In Hungary, the number of hospitalized RVGE cases was
derived from data obtained on authors’ request from the
Hungarian National Health Fund (OEP) for 2012. Our study
showed that in Hungary, only 33% of RVGE cases are reported
as under A08.0 code (1413 children o5 years in 2012), and hence
the total true number of RVGE cases requiring hospitalization can
be estimated as 4282 because many other real RV-positive cases
were reported by physicians under other DRG (ICD-10) codes, as
our chart review showed.
In Poland, publicly available data published once per annum
by the National Healthcare Fund (NFZ) include only the hospi-
talized RVGE cases, reported within a broad reference group
labeled P22 (infectious and noninfectious stomach and intestine
inﬂammations in patients aged 0–18 years). To obtain a speciﬁc
number of RVGE cases in those younger than 5 years (17,794
children in 2012), additional speciﬁcations had to be provided by
the National Healthcare Fund upon authors’ request.Table 1 – Length of hospital stay in days by age group an
Age group (mo) Czech Republic Hunga
o12 5.8 (3.0–13.0; 23) 6.9 (3.0–16
12–23 5.0 (3.0–12.0; 33) 5.1 (2.0–10
24–35 4.1 (3.0–8.0; 18) 5.4 (3.0–8.0
36–47 4.6 (3.0–7.0; 19) 5.1 (3.0–10
48–59 4.3 (2.0–7.0; 16) 4.1 (2.0–7.0
Total 4.9 (2.0–13.0; 109) 5.6 (2.0–16
Note. Values are shown as mean (minimum–maximum; N).Similar to the Czech Republic, reporting of infectious diseases
into their surveillance system called EPIS is mandatory in
Slovakia as dictated by Act No. 355/2007. In total, 2560 RVGE
cases in children younger than 5 years reported in 2012 served as
the basis for extrapolation.
Starting with the total number of RVGE cases, the extrapola-
tion rules as published by Soriano-Gabarro et al. [7] helped us to
roughly reproduce the whole RVGE burden of disease across all
severity grades. The approach is based on empirical observation
that for each child hospitalized, approximately 8 children (range
5–10) require a visit to a health care facility or physician’s ofﬁce,
and that for each child requiring medical care, approximately 4
children are treated at home.
Statistical Analysis
Descriptive statistics were applied to metric and categorical data
using SAS 9.3 (SAS Institute, Inc., Cary, NC) for Windows. The
data were classiﬁed by country to permit national comparisons.
No formal study hypothesis was deﬁned.Results
Study Population
The retrospective chart reviews were accomplished by 14 Czech
centers in 7 days, by 10 Hungarian centers in 51 days, by 9 Polish
centers in 32 days, and by 14 Slovak centers in 14 days. The mean
(minimum to maximum) age was 26.4 (1–60) months in the Czech
Republic, 21.9 (1–57) months in Hungary, 20.1 (0–56) months in
Poland, and 21.4 (0–58) months in Slovakia. No deaths due to
RVGE were reported in the assessed period.
Resource Use
The mean (minimum to maximum) length of stay across all age
groups was 4.9 (2–13) days in the Czech Republic, 5.6 (2–16) days
in Hungary, 5.2 (2–19) days in Poland, and 5.1 (3–18) days in
Slovakia. The longest stay was consistently observed in the group
of patients younger than 12 months in all countries, with a
tendency to decrease toward older ages (Table 1). In the Czech
Republic, 35% of patients stayed in the intensive care unit for at
least 1 day, with a mean length of stay of nearly 3 days.
The most frequently used RV diagnostic tests during hospital-
ization were immunochromatography in Hungary, Poland, and
Slovakia (78%, 99%, and 93% of cases, respectively) and latex
agglutination in the Czech Republic (44% of cases) (Table 2). The
second most frequent RV diagnostic tests used during hospital-
ization were latex agglutination in Hungary, Slovakia, and Poland
(14%, 7%, and 1% of cases, respectively) and immunochromatog-
raphy in the Czech Republic (39% of cases).
Among other tests performed during hospitalization, the most
frequent were biochemistry C-reactive protein (97% of cases) ind country and the number of subjects in each group.
ry Poland Slovakia
.0; 30) 6.3 (5.0–19.0; 36) 5.8 (2.5–14.0; 38)
.0; 37) 5.0 (4.0–12.0; 38) 4.7 (3.0–9.0; 33)
; 22) 4.5 (4.0–8.0; 23) 4.6 (3.0–7.0; 17)
.0; 11) 3.6 (3.5–5.0; 8) 4.5 (3.0–6.0; 15)
; 9) 4.7 (5.0–7.0; 7) 5.0 (3.0–8.0; 11)
.0; 109) 5.2 (2.0–19.0; 112) 5.1 (3.0–18.0; 115)
Table 2 – Frequency (%) of RV diagnostic test and other tests used.
Test used Czech Republic
(n ¼ 109)
Hungary
(n ¼ 109)
Poland
(n ¼ 112)
Slovakia
(n ¼ 115)
RV diagnostic test
ELISA 23 7 0 1
Latex agglutination 44 14 1 7
Immunochromatography 39 78 99 93
PCR 0 0 0 1
Other 0 1 0 0
Other tests performed during hospitalization
Biochemistry, chlorides 84 51 61 98
Biochemistry, ALT 91 42 81 90
Biochemistry, C-reactive protein 97 86 99 97
Biochemistry, potassium 92 88 100 98
Biochemistry, sodium 92 88 100 98
Blood cell counts with differential 87 83 100 82
Glucose—quantitative determination 82 60 70 97
Stool culture 89 91 39 97
Urinalysis chemically and microscopically 93 82 93 95
Note. In the Czech Republic and Slovakia, more than one RV diagnostic test might have been used simultaneously.
ALT, alanine aminotransferase; ELISA, enzyme-linked immunosorbent assay; PCR, polymerase chain reaction; RV, rotavirus.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 1 0 C ( 2 0 1 6 ) 5 3 – 6 056the Czech Republic; stool culture (91%) in Hungary; biochemistry
sodium, potassium, and blood counts (100%) in Poland; and
biochemistry sodium, chlorides, and potassium (98%) in Slovakia
(Table 2).
Intravenous rehydration was applied in 84% of cases in the
Czech Republic, 95% in Hungary, 99% in Poland, and 97% in
Slovakia.
The routes of hospital admission by country are presented in
Table 3. In the Czech Republic and Slovakia, patients were admitted
to hospital mainly via the emergency unit (45% and 61%, respec-
tively), whereas in Hungary and Poland, the most prevalent route
for admission to hospital was following a visit to a general pediatric
practitioner (43% and 41%, respectively). The pathway followed by
patients also differed between countries (Table 3). In all four
countries, most of the patients arrived at hospital after previous
outpatient contact and were followed-up again in an outpatient
setting after hospitalization (65% in the Czech Republic, 70% in
Hungary, 66% in Poland, and 98% in Slovakia).
The types of medication used by country and type of facility
are presented in Table 4. The largest differences betweenTable 3 – Frequency (%) of route of hospital admission an
requiring hospitalization.
Patient pathway & admission Czech Republic
(n ¼ 109)
Route of admission
Emergency 45
Central admission 21
GPP referral 34
Other 0
Patient pathway
Direct hospital admission, no FU 4
Hospital - outpatient FU 17
Outpatient- hospital- outpatient FU 65
Outpatient - hospital 14
FU, follow-up examination in another outpatient setting or in the hos
practitioner; RVGE, rotavirus gastroenteritis.countries were observed in the use of probiotics, whereas the
smallest differences related to the use of anti-inﬂammatories.
A speciﬁc question added for Poland revealed that for 100% of
the children hospitalized, one of the parents stayed in the
hospital for the whole duration of hospitalization.
Costs
An overview of the total cost by type of facility, including the
costs incurred before and after hospitalization, is presented in
Table 5.
Considering hospitalization costs alone, the discrepancy
observed between the truly reimbursed costs (DRG or contractual
reimbursement) and the costs as calculated by microcosting
varied by country. Using microcosting analysis, the estimated
average costs of treating an RVGE inpatient case including
prehospitalization and posthospitalization costs were €476,
€316, €741, and €594 in the Czech Republic, Hungary, Poland,
and Slovakia, respectively. In Slovakia, where the DRG system is
not in place, reimbursement levels are subject to individuald treatment pathways for patients with severe RVGE
Hungary
(n ¼ 109)
Poland
(n ¼ 112)
Slovakia
(n ¼ 115)
20 28 61
24 31 1
43 41 34
13 0 4
1 1 0
23 30 1
70 66 98
6 3 1
pital following discharge from the hospital; GPP, general pediatric
Table 4 – Medication used during hospital stay by type of ward/department and country.
Medication class Czech Republic Hungary Poland Slovakia
INF PED TOT INF PGE TOT COU REG UNI TOT INF PED TOT
Anti-inﬂammatories (%) 43 65 59 58 48 56 50 58 50 53 70 56 58
Antidiarrheal (%) 3 41 30 21 36 25 60 6 42 38 45 46 46
Antibiotics (%) 23 16 18 15 32 19 27 22 8 21 15 9 10
Probiotics (%) 40 80 69 25 48 30 75 58 96 74 20 73 63
Total number of patients 30 79 109 84 25 109 52 36 24 112 20 95 115
COU, county hospital; INF, infectious disease wards; PED, pediatric wards; PGE, pediatric gastroenterology; REG, regional hospital; TOT, total;
UNI, university hospital.
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inpatient settings in Slovakia can be due to the inclusion of an
extreme observation in one of the only two infectious disease
settings involved (Table 5). The overall national structure of costs
obtained by microcosting is shown in Figure 1. The cost of the
hospital stay was the dominant source of expenditure in all four
countries, representing 82% to 91% of the total cost.
Burden of Disease
There were in total 1.19 million cases of RVGE in the four
countries, of which 29,130 required hospitalization, 233,039 were
treated as outpatients, and 932,154 were mild cases treated at
home. The burden of disease estimated for all three severity
degrees and four countries is presented in Table 6.
On the basis of the number of cases, the total annual cost of
severe RVGE from the payer’s perspective in children younger
than 5 years was estimated at €2.1 million in the Czech Republic,
€1.5 million in Hungary, €13.2 million in Poland, and €1.5 million
in Slovakia, giving a total of €18.2 million in the V4.Discussion
The main reason for conducting this study was to provide
sufﬁciently robust underlying data to facilitate health economic
evaluations that are now fundamental to any discussion between
protagonists of vaccination programs and payers. Although some
useful epidemiology ﬁgures on RVGE are available already from
secondary databases, the resource use and costs data essential to
any health economic consideration have been missing. So far,
only rough estimates on costs associated with the treatment ofTable 5 – Total costs (€) by type of facility and country in
Cost Czech R
(n ¼
Microcosting in hospital
Infectious disease setting 396.8 (
Pediatric setting 506.7 (
County hospital
Regional hospital
University hospital
Pediatric gastroenterology
Average total hospital costs 46
Average total costs (including prehospitalization and
posthospitalization costs)
47
DRG or contractual reimbursement 483 (
DRG, diagnosis related group.RVGE were available, or the costs were largely neglected because
gastroenteritis is frequently perceived as only a minor impair-
ment not requiring more than a single consultation of a family
practitioner or pediatrician.
Since 2006, two RV vaccines have been available in Europe
(Rotarix [GSK Biologicals, Rixensart, Belgium] and RotaTeq [Merck
and Co., Inc., Kenilworth, NJ]). This has triggered studies estimat-
ing the economic burden of RV disease. The WHO has also
recommended that economic aspects should be included in
decision making about the potential introduction of a nationwide
RV vaccination program, in their positive position toward RV
vaccination [32]. A recently conducted cost-effectiveness evalua-
tion in Germany revealed incremental costs of €184 to prevent
one RVGE case and €2457 to prevent one RV-driven hospital-
ization when using Rotarix vaccine compared with no vaccina-
tion [33]. Results from lower income EU countries, such as the V4
countries studied here, are expected to differ from the German
ﬁgures, largely because of differences in cost structures. The DRG
system has been established in the Czech Republic, Hungary, and
Poland in recent years with the aim of standardizing the reim-
bursement of inpatient costs. In Slovakia, the discussion on DRG
introduction was ongoing and no implementation had yet taken
place at the time of this study. It has been shown that the true
costs may differ signiﬁcantly from the DRG costs, if considered in
detail using the microcosting approach [34].
In our analysis, the total cost for treating RVGE in hospital was
considerably different among countries. The total cost was
almost 2.5-fold higher in Poland than in Hungary. The best accord
between real resource-use-driven costs and the DRG cost was in
the Czech Republic and Hungary, with a difference of only €22
and €33, respectively. In Poland, however, the microcostingcluding costs incurred before and after hospital stay.
epublic
109)
Hungary
(n ¼ 109)
Poland
(n ¼ 112)
Slovakia
(n ¼ 115)
n ¼ 30) 320.8 (n ¼ 84) 1126.8 (n ¼ 20)
n ¼ 79) 481.8 (n ¼ 95)
740.0 (n ¼ 52)
701.2 (n ¼ 36)
804.3 (n ¼ 24)
298.1 (n ¼ 25)
0.9 306.2 716.9 577.6
6.4 315.6 741.3 594.0
DRG) 273 (DRG) 522 (DRG) 520 (Contractual)
Fig. 1 – The national structure of costs of RVGE requiring hospitalization as reproduced by microcosting analysis. CR, Czech
Republic; HU, Hungary; PL, Poland; RVGE, rotavirus gastroenteritis; SK, Slovakia.
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difference exceeding €190. Such a discrepancy has also been
previously reported for the treatment of community-acquired
pneumonia [34]. In Poland, published price lists were applied in
case of medical care provided to uninsured beneﬁciaries, includ-
ing a higher margin. This explains why the expenses determined
by this method could diverge from the “real prices” of medical
care as seen from the payer’s perspective. The Slovak system isTable 6 – Annual burden of RV disease in children young
Country Cases
Hospitalized cases
(severe RVGE)
GPP visits
(medium RVGE)
No visit
(mild RVG
Czech
Republic
4,494 35,952 143,808
Hungary 4,282 (1,413)* 34,255 137,018
Poland 17,794 142,352 569,408
Slovakia 2,560 20,480 81,920
GPP, general pediatric practitioner; RV, rotavirus; RVGE, rotavirus gastro
* A total of 1413 cases reported with code A08.0.based on bilateral contracts between hospitals and health funds,
and unfortunately offers limited accuracy to power any similar
quantitative analysis. The ordered by size expenditures for RVGE
treated in hospital as provided herein correlate with the health
expenditure per capita for the Czech Republic, Hungary, and
Slovakia (1,982; 1,839; and 12,147 purchasing power parity US $
2013) [35]. Discordant with this pattern, Poland shows dispropor-
tionally high calculated costs for treating RVGE requiring hospitaler than 5 y.
Incidence per 100,000
s
E)
Hospitalized cases
(severe RVGE)
GPP visits
(medium RVGE)
No visits
(mild RVGE)
761 6,090 24,360
909 7,273 29,085
865 6,923 27,692
884 7,073 28,292
enteritis.
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purchasing power parity US $ 2013]). The costs in Poland are
the highest among the four countries regardless of whether they
are based on DRG or microcosting. Another relative comparison
of the RVGE expenditures can be facilitated by comparing it with
the net average wages, ranging from €570 (Hungary) to €793 (the
Czech Republic) as provided by Eurostat.
The low prehospitalization and posthospitalization costs
identiﬁed in this study show that the different pathways followed
by patients with severe RVGE have a relatively limited economic
impact, compared with the cost of the hospitalization. Our
estimate of the extrapolated overall economic burden of severe
RVGE from the payer’s perspective, including expenditures
incurred in either outpatient or inpatient treatment, amounted
to €18.2 million in the V4, which should be considered rather a
very conservative estimation because it is generally recognized
that the public RVGE records are underestimated. This refers only
to direct costs and does not consider the indirect costs associated
with, for example, the absence from work of parents who often
accompany their children to hospital. This can be considered a
major limitation of this study. The data were collected at
hospitals, and hence are very detailed as to resource use during
the hospital stay. The costs incurred before and after admission
could be estimated only on the basis of reimbursement codes
(individual medical consulting) without deeper investigation of
individual medication and examinations use. For RVGE, however,
the medication cost for the payer during initial and follow-up
medical consultation is believed to be negligible (typically anti-
pyretics) and rather paid out of the patient’s pocket. During the
hospitalization though, the patient typically incurs no costs.
Regarding indirect costs for the society, a speciﬁc question added
in Poland revealed that for 100% of the infants hospitalized, one
of the parents also stayed in hospital during the whole hospital-
ization period. This absence from work/daily activities highlights
that a case of severe pediatric RVGE represents an important
burden for the family. Although this was not addressed in the
other participating countries, it is expected to be similar. These
indirect costs are often not presented to the payer or national
regulator, yet they may represent a signiﬁcant burden for the
family, especially when both parents are full-time employees. In
addition, it has been shown that parents of a child with acute
RVGE experience worry, distress, and disruptions in daily life as a
result of the child’s illness, with a trend toward higher impact on
parents’ daily activities and higher parental distress as the
severity of symptoms increases [36].
Nosocomial infections were not considered in this study. It
has been suggested that nosocomial RVGE may affect as many
children as can community-acquired RVGE [37]. Nosocomial RV
infections impose a major burden among all other hospital-
acquired infections, and data on their incidence are largely
missing or underreported, often because of the limitations in
conducting such studies [38]. Conducting a nonbiased study to
evaluate nosocomial infections may be technically very challeng-
ing because a proportion of patients may manifest symptoms
after discharge, thus obscuring the association to the primary
source of the infection.Conclusions
We conclude that RVGE in children, especially if it leads to
hospitalization, imposes a substantial economic burden on
payers, predominantly because of the costs of hospital stay.
RVGE deserves increased attention in a European context for its
economic impact, which could be substantially offset by preven-
tion programs such as nationwide vaccination of infants.Acknowledgments
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